862 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-ZC-FT-356394 Feb 22, 2019 - The index endured a holiday-shortened but volatile week.
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/355599/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-355599 Feb 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Intercept Reports Positive Top-Line Data for NASH, Shares Up http://www.zacks.com/stock/news/355517/intercept-reports-positive-top-line-data-for-nash-shares-up?cid=CS-ZC-FT-355517 Feb 20, 2019 - Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10. ... http://www.gurufocus.com/news/819032/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-109-million-of-shares Feb 19, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10.9 million of Shares, Stocks: MRK, release date:Feb 19, 2019
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster https://www.fool.com/investing/2019/02/19/pfizers-forgotten-cancer-pill-is-about-to-become-i.aspx?source=iedfolrf0000001 Feb 19, 2019 - A drug that disappointed in 2018 will get an unexpected dance at the big ball.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

Pages: 1...678910111213141516...87

<<<Page 11>